Synergy of GSK-J4 With Doxorubicin in KRAS-Mutant Anaplastic Thyroid Cancer

Synergy of GSK-J4 With Doxorubicin in KRAS-Mutant Anaplastic Thyroid Cancer

BackgroundAnaplastic thyroid cancer is the most aggressive thyroid cancer and has a poor prognosis. At present, there is no effective treatment for it.MethodsHere, we used different concentrations of GSK-J4 or a combination of GSK-J4 and doxorubicin to treat human Cal-62, 8505C, and 8305C anaplastic...

Full description

Bibliographic Details
Main Authors: Bo Lin, Bing Lu, I-yun Hsieh, Zhen Liang, Zicheng Sun, Yang Yi, Weiming Lv, Wei Zhao, Jie Li
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-05-01
Series:Frontiers in Pharmacology
Subjects:
anaplastic thyroid cancer
epigenetics
GSK-J4
synergistic action
KRAS-mutant
Online Access:https://www.frontiersin.org/article/10.3389/fphar.2020.00632/full

Internet

https://www.frontiersin.org/article/10.3389/fphar.2020.00632/full

Similar Items